169 related articles for article (PubMed ID: 34845439)
21. Clinical efficacy and immunological impact of tacrolimus in Chinese patients with generalized myasthenia gravis.
Zhao CB; Zhang X; Zhang H; Hu XQ; Lu JH; Lu CZ; Xiao BG
Int Immunopharmacol; 2011 Apr; 11(4):519-24. PubMed ID: 21195813
[TBL] [Abstract][Full Text] [Related]
22. Long-term therapeutic efficacy and safety of low-dose tacrolimus (FK506) for myasthenia gravis.
Tada M; Shimohata T; Tada M; Oyake M; Igarashi S; Onodera O; Naruse S; Tanaka K; Tsuji S; Nishizawa M
J Neurol Sci; 2006 Aug; 247(1):17-20. PubMed ID: 16631797
[TBL] [Abstract][Full Text] [Related]
23. Five-year follow-up with low-dose tacrolimus in patients with myasthenia gravis.
Minami N; Fujiki N; Doi S; Shima K; Niino M; Kikuchi S; Sasaki H
J Neurol Sci; 2011 Jan; 300(1-2):59-62. PubMed ID: 21035148
[TBL] [Abstract][Full Text] [Related]
24. A multicenter prospective observational study on the safety and efficacy of tacrolimus in patients with myasthenia gravis.
Ahn SW; Joo IS; Kim BJ; Sung JJ; Kang SY; Oh J; Minn YK; Suh BC; Oh SY; Hong YH; Nam TS; Seok JI; Park YE; Shin HY; Cho EB; Shin JY; Seok HY; Park JS; Min JH; Seok JM; Kim BJ
J Neurol Sci; 2017 Aug; 379():271-275. PubMed ID: 28716258
[TBL] [Abstract][Full Text] [Related]
25. Tacrolimus hydrate (FK506): therapeutic effects and selection of responders in the treatment of myasthenia gravis.
Wakata N; Saito T; Tanaka S; Hirano T; Oka K
Clin Neurol Neurosurg; 2003 Dec; 106(1):5-8. PubMed ID: 14643908
[TBL] [Abstract][Full Text] [Related]
26. Ocular myasthenia gravis patients following the administration of tacrolimus and steroids.
Omata T; Fukui K; Kodama K; Watanabe Y; Aoyama H; Fujii K; Shimojo N
J Neurol Sci; 2019 Jan; 396():30-32. PubMed ID: 30399462
[No Abstract] [Full Text] [Related]
27. Tacrolimus monotherapy: a promising option for ocular myasthenia gravis.
Yagi Y; Sanjo N; Yokota T; Mizusawa H
Eur Neurol; 2013; 69(6):344-5. PubMed ID: 23549260
[No Abstract] [Full Text] [Related]
28. Clinical efficacy of tacrolimus for treating myasthenia gravis and its influence on lymphocyte subsets.
Bao J; Gao S; Weng Y; Zhu J; Ye H; Zhang X
Rev Neurol (Paris); 2019; 175(1-2):65-72. PubMed ID: 30293884
[TBL] [Abstract][Full Text] [Related]
29. Minimal manifestation status and prednisone withdrawal in the MGTX trial.
Lee I; Kuo HC; Aban IB; Cutter GR; McPherson T; Kaminski HJ; Sussman J; Ströbel P; Oger J; Cea G; Heckmann JM; Evoli A; Nix W; Ciafaloni E; Antonini G; Witoonpanich R; King JO; Beydoun SR; Chalk CH; Barboi AC; Amato AA; Shaibani AI; Katirji B; Lecky BRF; Buckley C; Vincent A; Dias-Tosta E; Yoshikawa H; Waddington-Cruz M; Pulley MT; Rivner MH; Kostera-Pruszczyk A; Pascuzzi RM; Jackson CE; Verschuuren JJG; Massey JM; Kissel JT; Werneck LC; Benatar M; Barohn RJ; Tandan R; Mozaffar T; Conwit R; Minisman G; Sonett JR; Wolfe GI;
Neurology; 2020 Aug; 95(6):e755-e766. PubMed ID: 32611638
[TBL] [Abstract][Full Text] [Related]
30. [Current concept and perspective of immunotherapy for myasthenia gravis: tacrolimus and cyclosporin].
Yokoyama K
Nihon Rinsho; 2008 Jun; 66(6):1158-64. PubMed ID: 18540363
[TBL] [Abstract][Full Text] [Related]
31. Successful treatment of a 2-year-old girl with intractable myasthenia gravis using tacrolimus.
Kakisaka Y; Haginoya K; Yokoyama H; Ishitobi M; Wakusawa K; Sato I; Togashi N; Kitamura T; Fukuyo N; Yoshihara Y; Iinuma K
Brain Dev; 2006 Sep; 28(8):534-6. PubMed ID: 16564661
[TBL] [Abstract][Full Text] [Related]
32. [Pre-evening meal administration of tacrolimus improved refractory ocular symptoms in two young children with latent general myasthenia gravis].
Yoshikawa Y; Ishigaki K; Shishikura K; Hirasawa K; Sato T; Suzuki H; Hirayama Y; Osawa M
No To Hattatsu; 2013 Jul; 45(4):318-22. PubMed ID: 23951946
[TBL] [Abstract][Full Text] [Related]
33. Effective treatment of a 13-year-old boy with steroid-dependent ocular myasthenia gravis using tacrolimus.
Mori T; Mori K; Suzue M; Ito H; Kagami S
Brain Dev; 2013 May; 35(5):445-8. PubMed ID: 22840813
[TBL] [Abstract][Full Text] [Related]
34. Successful treatment of myasthenia gravis with tacrolimus.
Evoli A; Di Schino C; Marsili F; Punzi C
Muscle Nerve; 2002 Jan; 25(1):111-4. PubMed ID: 11754194
[TBL] [Abstract][Full Text] [Related]
35. Immunosuppressive agents for myasthenia gravis.
Hart IK; Sathasivam S; Sharshar T
Cochrane Database Syst Rev; 2007 Oct; (4):CD005224. PubMed ID: 17943844
[TBL] [Abstract][Full Text] [Related]
36. Safety of tapering tacrolimus dose in patients with well-controlled anti-acetylcholine receptor antibody-positive myasthenia gravis.
Nishida Y; Takahashi YK; Kanai T; Nose Y; Ishibashi S; Sanjo N; Uzawa A; Oda F; Ozawa Y; Kuwabara S; Noguchi E; Suzuki S; Nakahara J; Suzuki N; Ogawa T; Yokoyama K; Hattori N; Konno S; Fujioka T; Kawaguchi N; Hatanaka Y; Sonoo M; Kaneko J; Ogino M; Nishiyama K; Nomura K; Yokota T
Eur J Neurol; 2020 Jan; 27(1):100-104. PubMed ID: 31309642
[TBL] [Abstract][Full Text] [Related]
37. Beneficial effect of tacrolimus on myasthenia gravis with thymoma.
Mitsui T; Kunishige M; Ichimiya M; Shichijo K; Endo I; Matsumoto T
Neurologist; 2007 Mar; 13(2):83-6. PubMed ID: 17351528
[TBL] [Abstract][Full Text] [Related]
38. Experience with starting tacrolimus postoperatively after transsternal extended thymectomy in patients with myasthenia gravis.
Ponseti JM; Azem J; Fort JM; López-Cano M; Vilallonga R; Gamez J; Armengol M
Curr Med Res Opin; 2006 May; 22(5):885-95. PubMed ID: 16709310
[TBL] [Abstract][Full Text] [Related]
39. [The clinical efficacy and safety of tacrolimus in patients with myasthenia gravis].
Chen YP; Wang W; Wang ZK; Wei DN; Zhang J
Zhonghua Nei Ke Za Zhi; 2013 Jul; 52(7):567-9. PubMed ID: 24266997
[TBL] [Abstract][Full Text] [Related]
40. Comparison between mono-tacrolimus and mono-glucocorticoid in the treatment of myasthenia gravis.
Fan Z; Lei L; Su S; Zhang S; Xie N; Li L; Lu Y; Di L; Wang M; Xu M; Shen XM; Da Y
Ann Clin Transl Neurol; 2023 Apr; 10(4):589-598. PubMed ID: 36808840
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
